evaluating bavituximab

Related by string. * EVALUATING . EVALUATED . Evaluated . evaluated . Evaluating : evaluating CK # . rigorously evaluated . When evaluating Antigenics . Intervention Trial Evaluating . evaluating OGX . prospectively evaluated . evaluating Nexavar . evaluating ispinesib / Bavituximab : bavituximab monotherapy trial . PS bavituximab . Peregrine bavituximab . candidates bavituximab . bavituximab * *

Related by context. Frequent words. (Click for all words.) 62 paclitaxel carboplatin 60 HGS ETR2 60 R sorafenib tablets 59 Phase Ib II 58 Initiates Phase II 58 deforolimus 58 liposomal formulation 57 phase Ib 57 teriflunomide 57 plus gemcitabine 57 pertuzumab 57 metastatic castration resistant 57 Cloretazine R VNP#M 56 Pivotal Phase 56 axitinib 56 KRN# 56 forodesine 56 iniparib 56 docetaxel chemotherapy 56 paclitaxel chemotherapy 56 relapsed refractory multiple myeloma 55 carboplatin paclitaxel 55 Initiate Phase 55 plus prednisone 55 Meets Primary Endpoint 55 enzastaurin 55 sunitinib malate 55 phase 2a 55 phase IIa 55 metastatic hormone refractory 55 phase IIb clinical 54 tanespimycin 54 elotuzumab 54 ongoing Phase 1b 54 plus dexamethasone 54 Phase 2a clinical 54 stereotactic body 54 Vytorin combines 54 IMC A# 54 confirmatory Phase III 53 Pivotal Phase III 53 FOLFIRI 53 GRN#L 53 nab paclitaxel 53 relapsing multiple sclerosis 53 Phase 1b clinical 53 ThermoDox R 53 nonrandomized 53 pegylated interferon alpha 53 Platinol 53 relapsed multiple myeloma 53 blind multicenter 53 ganetespib 53 mycophenolate mofetil 53 subcutaneous formulation 53 Phase Ib clinical 53 Daclizumab 52 phase IIb 52 Amrubicin 52 HGS ETR1 52 ponatinib 52 phase IIa clinical 52 Entereg R 52 dose escalation trial 52 NVA# 52 dose regimens 52 Imprime PGG 52 multi kinase inhibitor 52 placebo controlled clinical 52 Locteron ® 52 OMS# 52 multicenter Phase 52 vascular disrupting agent 51 Phase IIa trials 51 double blinded randomized 51 Phase IIIb 51 systemically administered 51 Roflumilast 51 multicenter prospective 51 ABSORB trial 51 bendamustine 51 Phase 2b clinical 51 Phase 1b 51 preclinical efficacy 51 PEG SN# 51 orBec 51 bicifadine 50 GRNVAC1 50 Phase 2b clinical trials 50 dose escalation 50 Tekamlo 50 peginterferon alfa 2b 50 double blinded placebo 50 Pivotal Trial 50 dacarbazine 50 TAXUS IV 50 anti arrhythmic 50 placebo controlled Phase 50 EVEREST II 50 primary hypercholesterolemia 50 GV# [001]

Back to home page